AVLN vs BBOT: fair value comparison
Avalyn Pharma Inc. and BridgeBio Oncology Therapeutics, Inc. · Updated 2026-10-19
AVLN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. BBOT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AVLN currently ranks higher by quality score.
| AVLN | BBOT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $23.66 | $2.82 |
| 12-month range | $23.66–$35.28 | $2.82–$13.73 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #221 of 301 Healthcare | #223 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | — | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AVLN fair value analysis · BBOT fair value analysis